Faster access to better and safer medicines

A potential drawback of clinical trials of new drugs is that they do not always reflect how well these will work in the 'real world'. EU and industry-funded research brought together key stakeholders to help add more such evidence into the design of trials, increasing confidence in new medicines and helping to get them to patients more quickly.

Countries
Countries
  Algeria
  Argentina
  Australia
  Austria
  Bangladesh
  Belarus
  Belgium
  Benin
  Bolivia
  Botswana
  Brazil
  Bulgaria
  Burkina Faso
  Cambodia
  Cameroon
  Canada
  Cape Verde
  Chile
  China
  Colombia
  Costa Rica
  Croatia
  Cyprus
  Czech Republic
  Denmark
  Ecuador
  Egypt
  Estonia
  Ethiopia
  Faroe Islands
  Finland
  France
  French Polynesia
  Gambia
  Georgia

Countries
Countries
  Algeria
  Argentina
  Australia
  Austria
  Bangladesh
  Belarus
  Belgium
  Benin
  Bolivia
  Botswana
  Brazil
  Bulgaria
  Burkina Faso
  Cambodia
  Cameroon
  Canada
  Cape Verde
  Chile
  China
  Colombia
  Costa Rica
  Croatia
  Cyprus
  Czech Republic
  Denmark
  Ecuador
  Egypt
  Estonia
  Ethiopia
  Faroe Islands
  Finland
  France
  French Polynesia
  Gambia
  Georgia


  Infocentre

Published: 28 February 2018  
Related theme(s) and subtheme(s)
Health & life sciencesDrugs & drug processes  |  Medical research
Countries involved in the project described in the article
Belgium  |  Denmark  |  France  |  Germany  |  Greece  |  Netherlands  |  Sweden  |  Switzerland  |  United Kingdom  |  United States
Add to PDF "basket"

Faster access to better and safer medicines

GetReal infographic

© GetReal, 2017

Trials of healthcare interventions are often described as either explanatory or pragmatic. Explanatory trials generally measure efficacy – the proven benefits of a treatment in ideal conditions and with standardised subjects. Pragmatic trials measure effectiveness – the benefit of a treatment in routine clinical practice and with all patients eligible for treatment who generally have a broader range of diseases or risk factors.

The EU- and industry-funded GETREAL project was designed to help bridge the gap between efficacy and effectiveness by showing how new methods of real world evidence (RWE) collection and synthesis could be developed and considered for adoption earlier in pharmaceutical research and development (R&D) and the healthcare decision-making process.

The project broke ground in that it brought together companies, healthcare decision makers, patient representatives and other stakeholders to generate a consensus on best practice in the use of RWE in drug development, as well as regulatory and reimbursement decision-making.

It is hoped that the alternative evidence-generating strategies developed will deliver more focused research in pharmaceutical R&D and allow healthcare decision makers to be more confident when giving patients access to new treatments.

“Uncertainty slows things down with regard to getting new medicines to market,” says Chris Chinn, GETREAL’s deputy project coordinator. “Social and economic benefits should follow if we have been successful in helping individual research teams work with the healthcare decision makers to define evidence-based studies that ensure effective medicines have a smoother path to patients, freeing up research capital for other projects and ensuring patients start to benefit sooner.”

Teaming up to improve study designs

GETREAL fostered an unprecedented level of cooperation between a broad range of stakeholders – including scientists, regulators, payers, physicians and patients – with the aim of discussing and evaluating the potential acceptability and usefulness of real world evidence for demonstrating the relative effectiveness of new drugs.

In December 2016, the project successfully launched the ‘RWE Navigator’, a publicly available real world evidence resource. It provides guidance on the use of real world data, real world study designs and synthesis of real world data to a broad range of potential users.

It also directs the user to a range of tools developed by GETREAL, including:

  • The TOOLBOX, a repository of tools and methods for better estimating the effectiveness of drugs ahead of market authorization;
  • PRAGMAGIC, a decision support tool developed to help users understand the complex interplay between design choices of pragmatic trials and their operational challenges, drawing on guidance and recommendations accumulated through methods reviews, case studies and stakeholder feedback;
  • ADDIS, an open source platform designed to help policymakers and researchers weigh the positive and negative effects of drugs. Giving guidance

GETREAL also hosted a series of webinars to support the dissemination of information and organised many cross-sector workshops and events attracting participants from academia, industry, regulatory bodies and patient organisations from across Europe.

“Although the groups did not ‘solve’ the research challenges for any particular disease, by looking at cases studies from cancer, chronic obstructive pulmonary disease and many other areas, they were able to develop tools and guidance that will help any research group work out their own solutions,” Chinn says.

GETREAL was funded by the Innovative Medicines Initiative, a public-private partnership between the EU and the European pharmaceutical industry. It plans to continue for a further two years with support from the European Federation of Pharmaceutical Industries and Associations (EFPIA) and IMI and then hopes to become a self-funding, sustainable European platform for innovation in real world medicines research.

Project details

  • Project acronym: GETREAL
  • Participants: UK (coordinator), Netherlands, Switzerland, Belgium, France, Greece, United States, Germany, Sweden, Denmark
  • Project N°: 115546
  • Total costs: € 16 436 328
  • EU contribution: € 8 000 000
  • Duration: October 2013 to March 2017

See also

 

Convert article(s) to PDF

No article selected


loading


Search articles

Notes:
To restrict search results to articles in the Information Centre, i.e. this site, use this search box rather than the one at the top of the page.

After searching, you can expand the results to include the whole Research and Innovation web site, or another section of it, or all Europa, afterwards without searching again.

Please note that new content may take a few days to be indexed by the search engine and therefore to appear in the results.

Print Version
Share this article
See also
Project website
Project details